Overview

A Study of Tofacitinib in Patients With Ulcerative Colitis in Stable Remission

Status:
Active, not recruiting
Trial end date:
2023-03-08
Target enrollment:
Participant gender:
Summary
This study is a follow up study for subjects with Ulcerative Colitis (UC) in stable remission designed to evaluate flexible dosing of CP-690,550.
Phase:
Phase 4
Details
Lead Sponsor:
Pfizer
Treatments:
Tofacitinib